Sara Nochur
Directeur/Membre du Conseil chez MARINUS PHARMACEUTICALS, INC.
Fortune : 9 017 $ au 30/04/2024
Postes actifs de Sara Nochur
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2021 | - |
| Conseiller Juridique Général | 01/01/2006 | 01/01/2021 | |
| MARINUS PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 22/03/2021 | - |
| Independent Dir/Board Member | 22/03/2021 | - | |
| Hospitality Homes | Président | 01/01/2021 | - |
| Biomedical Sciences Careers Program, Inc. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Sara Nochur
Anciens postes connus de Sara Nochur
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| DECIBEL THERAPEUTICS, INC. | Directeur/Membre du Conseil | 06/12/2021 | 22/09/2023 |
| Independent Dir/Board Member | 06/12/2021 | 22/09/2023 | |
| THE MEDICINES COMPANY | Conseiller Juridique Général | - | - |
| Biotrack, Inc. | Directeur des opérations | - | - |
| Conseiller Juridique Général | - | - | |
| DynaGen, Inc. | Corporate Officer/Principal | - | - |
Ischemix, Inc.
 Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Conseiller Juridique Général | - | - |
Formation de Sara Nochur
| Massachusetts Institute of Technology | Doctorate Degree |
| University of Mumbai | Graduate Degree |
Statistiques
Internationale
| Etats-Unis | 11 |
| Inde | 2 |
Opérationnelle
| General Counsel | 4 |
| Director/Board Member | 3 |
| Corporate Officer/Principal | 2 |
Sectorielle
| Health Technology | 7 |
| Finance | 2 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| MARINUS PHARMACEUTICALS, INC. | Health Technology |
| ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
| DECIBEL THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
The Medicines Co.
 The Medicines Co. Pharmaceuticals: MajorHealth Technology The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ. | Health Technology |
| DynaGen, Inc. | Health Technology |
| Biomedical Sciences Careers Program, Inc. | |
| Biotrack, Inc. | |
Ischemix, Inc.
Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Health Technology |
| Hospitality Homes |
- Bourse
- Insiders
- Sara Nochur
- Expérience
